recent
public
brought
attent
possibl
benefit
chloroquin
broadli
use
antimalari
drug
treatment
patient
infect
novel
emerg
coronaviru
colson
et
al
gao
et
al
scientif
commun
consid
inform
light
previou
experi
chloroquin
field
antivir
research
sulfat
phosphat
salt
chloroquin
commercialis
antimalari
drug
hydroxychloroquin
also
use
antimalari
addit
broadli
use
autoimmun
diseas
lupu
rheumatoid
arthriti
note
chloroquin
hydroxychloroquin
consid
safe
sideeffect
gener
mild
transitori
howev
margin
therapeut
toxic
dose
narrow
chloroquin
poison
associ
cardiovascular
disord
lifethreaten
friskholmberg
et
al
chloroquin
hydroxychloroquin
use
therefor
subject
strict
rule
selftreat
recommend
vitro
antivir
activ
chloroquin
identifi
sinc
late
inglot
miller
lenard
shimizu
et
al
growth
mani
differ
virus
inhibit
cell
cultur
chloroquin
hydroxychloroquin
includ
sar
coronaviru
keyaert
et
al
evid
activ
mice
found
varieti
virus
includ
human
coronaviru
keyaert
et
al
enteroviru
tan
et
al
zika
viru
li
et
al
influenza
yan
et
al
howev
chloroquin
prevent
influenza
infect
random
doubleblind
placebocontrol
clinic
trial
paton
et
al
effect
dengueinfect
patient
random
control
trial
vietnam
tricou
et
al
chloroquin
also
activ
ex
vivo
vivo
case
ebolaviru
mice
dowal
et
al
falzarano
et
al
nipah
pallist
et
al
influenza
viru
vigerust
mcculler
ferret
case
chikungunya
viru
chikv
specif
interest
chloroquin
show
promis
antivir
activ
vitro
coomb
et
al
delogu
de
lamballeri
shown
enhanc
alphaviru
replic
variou
anim
model
maheshwari
et
al
roqu
et
al
seth
et
al
probabl
immun
modul
antiinflammatori
properti
chloroquin
vivo
connolli
et
al
katz
russel
savarino
et
al
nonhuman
primat
model
chikv
infect
chloroquin
treatment
shown
exacerb
acut
fever
delay
cellular
immun
respons
lead
incomplet
viral
clearanc
roqu
et
al
clinic
trial
conduct
chikungunya
outbreak
island
show
oral
chloroquin
treatment
improv
cours
acut
diseas
de
lamballeri
et
al
chronic
arthralgia
day
postil
frequent
treat
patient
control
group
roqu
et
al
altogeth
assess
previou
trial
indic
date
acut
viru
infect
success
treat
chloroquin
human
chloroquin
also
test
chronic
viral
diseas
use
treatment
hivinfect
patient
consid
inconclus
chauhan
tikoo
drug
includ
panel
recommend
hiv
treatment
modest
effect
chloroquin
therapi
human
viru
infect
found
chronic
hepat
c
increas
earli
virolog
respons
pegyl
interferon
plu
ribavirin
helal
et
al
small
sampl
size
pilot
trial
nonrespond
hcv
patient
transient
viral
load
reduct
peymani
et
al
observ
enough
includ
chloroquin
standardis
therapeut
http
receiv
februari
receiv
revis
form
march
accept
march
protocol
hepat
c
patient
recent
wang
colleagu
wang
et
al
evalu
vitro
five
fdaapprov
drug
two
broad
spectrum
antivir
clinic
isol
one
conclus
chloroquin
highli
effect
control
infect
vitro
safeti
track
record
suggest
assess
human
patient
suffer
novel
coronaviru
diseas
least
differ
trial
alreadi
regist
chines
clinic
trial
registri
propos
use
chloroquin
hydroxychloroquin
treatment
chines
clinic
trial
regist
chictr
recent
public
gao
et
al
gao
colleagu
indic
accord
news
brief
result
patient
demonstr
chloroquin
phosphat
superior
control
treatment
inhibit
exacerb
pneumonia
improv
lung
imag
find
promot
viru
neg
convers
shorten
diseas
cours
would
repres
first
success
use
chloroquin
human
treatment
acut
viral
diseas
undoubtedli
excel
news
sinc
drug
cheap
wide
avail
howev
consid
care
draw
definit
conclus
sinc
data
provid
yet
support
announc
result
produc
ten
differ
hospit
possibl
number
differ
clinic
protocol
among
list
includ
variou
design
control
group
none
differ
antivir
placebo
etc
variou
outcom
primari
indic
final
interpret
therefor
technic
demand
absenc
publish
data
difficult
reach
firm
conclus
utmost
import
know
observ
efficaci
associ
specif
chloroquin
phosphat
includ
salt
eg
sulfat
chloroquin
hydroxychloroquin
also
necessari
determin
benefit
chloroquin
therapi
depend
age
class
clinic
present
stage
diseas
conclus
option
use
chloroquin
treatment
examin
attent
light
recent
promis
announc
also
potenti
detriment
effect
drug
observ
previou
attempt
treat
acut
viral
diseas
urg
chines
scientist
report
interim
trial
result
current
run
china
soon
avail
preferenti
done
peerreview
public
detail
inform
allow
intern
scientif
commun
analys
result
confirm
prospect
trial
efficaci
propos
treatment
guid
futur
clinic
practic
